Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker…
President Donald Trump signs an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images Several of the largest U.S. and European-based drugmakers inked deals with…
Novo Nordisk CEO Maziar Mike Doustdar shakes hands with U.S. President Donald Trump during an event to announce a deal with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White House in Washington, D.C., U.S., November 6, 2025. Jonathan Ernst |…
Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand…